目的:观察低功率超声空化治疗实体瘤的近期和远期疗效及不良反应。方法:53例晚期实体瘤患者随机分为超声空化+化疗组(A组18例)、单纯化疗组(B组18例)和单纯超声空化治疗组(C组17例)。超声空化治疗为每周治疗5d,1次/d,共治疗2周;或每周治疗3d,1次/d,共治疗3周。可同时进行化疗和超声空化治疗。结果:53例患者均可评价疗效和不良反应。A组中完全缓解1例、部分缓解6例、疾病稳定9例,临床获益率为88.89%(16/18);B组中无完全缓解患者、部分缓解4例、疾病稳定7例,临床获益率为61.11%(11/18);两组比较差异有统计学意义(P<0.05)。C组中无完全缓解患者、部分缓解4例、疾病稳定6例,临床获益率为58.82%(10/17)。A、B和C组的生活质量改善率分别为83.33%、55.56%和58.82%。A、B和C组的1年生存率分别为66.67%、44.44%和41.18%,2年生存率分别为38.89%、16.67%和17.65%。A组与B组和C组的1和2年生存率差异均有统计学意义(P<0.05);B组和C组的1和2年生存率差异无统计学意义(P>0.05)。超声空化治疗无血液学不良反应,主要不良反应为局部疼痛和发热,可自行缓解。结论:超声空化治疗晚期实体瘤的有效率较高,不良反应可以耐受,能够改善患者的生活质量。 OBJECTIVE: To observe the short-term and long-term effects and adverse reactions of low-power ultrasound in the treatment of solid tumors. Methods: Fifty-three patients with advanced solid tumors were randomly divided into three groups: group A (18 cases), group B (18 cases) and group C (group C). Ultrasound cavitation treatment for weekly treatment of 5d, 1 / d, a total of 2 weeks; or weekly treatment of 3d, 1 / d, a total of 3 weeks. Chemotherapy and ultrasound can be treated simultaneously. Results: All 53 patients were evaluated for efficacy and adverse reactions. A group of complete remission in 1 case, partial remission in 6 cases, 9 cases of stable disease, the clinical benefit rate was 88.89% (16/18); B group without complete remission in patients with partial remission in 4 cases, 7 cases of stable disease, clinical The rate of benefit was 61.11% (11/18). There was significant difference between the two groups (P <0.05). In group C there was no complete remission, with partial remission in 4 cases and stable disease in 6 cases. The clinical benefit rate was 58.82% (10/17). The quality of life improvement in groups A, B and C were 83.33%, 55.56% and 58.82%, respectively. The 1-year survival rates of groups A, B and C were 66.67%, 44.44% and 41.18% respectively, and the 2-year survival rates were 38.89%, 16.67% and 17.65% respectively. There was significant difference in 1-year and 2-year survival rates between group A and group B and group C (P <0.05). There was no significant difference in 1-year and 2-year survival between group B and group C (P> 0.05). Ultrasound cavitation treatment without hematological adverse reactions, the main adverse reactions of local pain and fever, can ease itself. Conclusion: Ultrasound cavitation treatment of advanced solid tumors with high efficiency, adverse reactions can be tolerated, can improve the quality of life of patients.